𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬 𝐰𝐢𝐭𝐡 𝐂𝐡𝐫𝐢𝐬 𝐆𝐚𝐫𝐚𝐛𝐞𝐝𝐢𝐚𝐧: Episode 1 | Venrock's Bryan Roberts. Bryan Roberts discusses Venrock's history, moving from NYC to the Bay Area, his investment philosophy, portfolio construction and concentration, the types of entrepreneurs he looks for, what qualities make for a good early stage investor, thoughts on AI, Tech Bio, and more. Full video: https://lnkd.in/gt3Agciv BiotechTV is brough to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
About us
News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
- Website
-
https://www.biotechtv.com
External link for BiotechTV
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- Seaport, Boston
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Biotech and News
Locations
-
Primary
Seaport, Boston, US
Employees at BiotechTV
Updates
-
𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐍𝐞𝐰𝐬: Travere Therapeutics' FILSPARI earned a conversion of its accelerated approval for IgA nephropathy into a full approval, a decision that came with an expanded label. CEO Eric Dube describes the drug's mechanism, the new population, and what else Travere is working on that will have near-term catalysts. Full video: https://lnkd.in/g-qCikbh BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐌𝐚𝐫𝐬𝐞𝐢𝐥𝐥𝐞: ImCheck Therapeutics' CEO Pierre d'Epenoux on targeting butyrophilin to modulate innate and adaptive immunity. He describes how activating butyrophilin modulates γδ t-cells, science that has largely been explored in Marseille, and covers ImCheck's current clinical programs. Plus, what it is like being a biotech company in this area. Full video: https://lnkd.in/gk7qcUwy BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐌𝐚𝐫𝐬𝐞𝐢𝐥𝐥𝐞: Innate Pharma Founder & CEO gives an overview of the company's programs and discusses Marseille's strengths in immunology Herve Brailly discusses lacutamab, monalizumab, the company's NK engager programs, and more. Full video: https://lnkd.in/gcxmFDhF BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐏𝐚𝐫𝐢𝐬: Paris Saclay Cancer Cluster (PSCC) is designed to support entrepreneurs and create an innovation ecosystem of oncology R&D right at Gustave Roussy. PSCC President Eric Vivier describes the facilities that are being built and other pillars of support that the cluster can offer cancer researchers to do their work in Paris. Full video: https://lnkd.in/gZ8-w4cN BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐏𝐚𝐫𝐢𝐬: Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest. CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector manufacturing. Plus, he shares an update on the company's fundraising, partnering, and wholly owned programs. Full video: https://lnkd.in/gbxpdeze BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐏𝐚𝐫𝐢𝐬: With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases. CEO Stephane Boissel describes the company's first gene therapy program, with seeks to treat retinitis pigmentosa regardless of the mutational cause, and the future of its CRISPR/Cas9 gene editing partnership with Intellia. Full video: https://lnkd.in/gRCAtS_u BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐅𝐫𝐨𝐦 𝐏𝐚𝐫𝐢𝐬: Enterome has an IO approach that is founded on learnings from how the gut interacts with the immune system. CEO Belichard Pierre describes the scientific underpinnings of this idea, and how it has lead to Enterome's programs, including one in NHL that has caught the attention of the Leukemia & Lymphoma Society and will have data around ASH time. Full video: https://lnkd.in/gF75rR_W BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐓𝐚𝐥𝐤𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Checking in with Imvax, Inc. ahead of key P2b data in glioblastoma next year of its personalized treatment that is delivered via implantable biodiffusion chambers. CEO John Furey describes how the therapy works, like a combination of "immunotherapy and cell therapy." He reviews phase 1 data, and previews key P2b data that is currently scheduled for mid-2025. Full video: https://lnkd.in/gHY6eKwF BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
BiotechTV reposted this
Excited to announce the first guest on the BioVenture VoiCes video podcast: Bryan Roberts of Venrock. Venrock was founded in 1969 and was a pioneer in VC investment in startups and one of the earliest biotech investors. Bryan joined Venrock in 1997 and has been a leading investor in many successful companies over that time and continues to be one of the most forward-thinking VCs across the healthcare landscape. My interview with Bryan will be posted early next week on BiotechTV (Brad Loncar's great platform for news and information) and I encourage you to take a listen. Follow BioVenture VoiCes to hear announcements about discussions with successful healthcare VC leaders!